Lower recall rates, more cancer detection were seen with 3D digital breast tomosynthesis, compared with 2D digital mammography.
Mammography screening with 3D digital breast tomosynthesis (DBT) yields lower recall rates and increased cancer detection, compared with 2D digital mammography (DM), according to a study published in the American Journal of Roentgenology.
Researchers from Fairfax, Va., Bethesda, Md. and Israel assessed the clinical performance of combined 2D-3D DBT compared with 2D DM alone for screening mammography in a community-based radiology practice. The study period ran from August 2011 to November 2012. Fourteen radiologists compared the screening mammographies - 23,149 patients with 3D DBT versus 54,684 patients with 2D DM.
The results showed better results with 3D DBT over 2D DM:
• 3D DBT had a 16.1 percent lower recall rate than did 2D DM
• Overall cancer detection rate was 28.5 percent greater for 3D DBT (6.3 per 1,000 compared with 4.9 per 1,000 for 2D DM)
• Invasive cancer detection was 43.8 percent higher for 3D DBT (4.6 per 1,000 compared with 3.2 per 1,000 with 2D DM)
• Positive predictive value for recalls from screening was 53.3 percent greater for 3D DBT (4.6 percent) compared with 2D DM (3.0 percent)
• There was no significant difference in the positive predictive value for biopsy for 3D DBT versus 2D DM (22.8 percent and 23.8 percent, respectively)
“We observed a significant increase in the detection rate for cancer overall and an even greater increase in the detection rate for invasive cancer,” coauthor Julianne Greenberg said in a release. “Our results may be a bellwether for the impact of tomosynthesis on population-based breast cancer screening.”
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.
Is the Kaiser Score More Effective than BI-RADS for Assessing Contrast-Enhanced Mammography and MRI?
October 14th 2024For women with breast-enhanced masses, Kaiser scoring (KS) demonstrated a 20 percent higher AUC than BI-RADS classification for contrast-enhanced mammography (CEM) and was comparable to KS for breast MRI.
FDA Clears New Features in AI-Powered Mammography Software Suite
October 11th 2024Therapixel’s MammoScreen suite has received 510(k) FDA clearances for a breast density assessment feature and updated software that includes automated pre-reporting, which reportedly expedites reporting of mammography findings.